Click for best price
IBSC Drugs Market Size, Share 2022
Market Analysis and Insights: Global IBSC Drugs Market
The global IBSC Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global IBSC Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global IBSC Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global IBSC Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global IBSC Drugs market.
Global IBSC Drugs Scope and Market Size
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes IBSC Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of IBSC Drugs, with price, sales, revenue, and global market share of IBSC Drugs from 2019 to 2022.
Chapter 3, the IBSC Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the IBSC Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the IBSC Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of IBSC Drugs.
Chapter 13, 14, and 15, to describe IBSC Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 IBSC Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global IBS-C Drugs Market Research Report 2023 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
116 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 IBS-C Drugs Market Overview
1.1 Product Overview and Scope of IBS-C Drugs
1.2 IBS-C Drugs Segment by Type
1.2.1 Global IBS-C Drugs Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Linaclotide
1.2.3 Lubiprostone
1.2.4 Osmotic Laxatives
1.2.5 Stimulant Laxatives
1.2.6 Others
1.3 IBS-C Drugs Segment by Application
1.3.1 Global IBS-C Drugs Sales Comparison by Application: (2023-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global IBS-C Drugs Market Size Estimates and Forecasts
1.4.1 Global IBS-C Drugs Revenue 2017-2030
1.4.2 Global IBS-C Drugs Sales 2017-2030
1.4.3 IBS-C Drugs Market Size by Region: 2017 Versus 2021 Versus 2030
2 IBS-C Drugs Market Competition by Manufacturers
2.1 Global IBS-C Drugs Sales Market Share by Manufacturers (2017-2023)
2.2 Global IBS-C Drugs Revenue Market Share by Manufacturers (2017-2023)
2.3 Global IBS-C Drugs Average Price by Manufacturers (2017-2023)
2.4 Manufacturers IBS-C Drugs Manufacturing Sites, Area Served, Product Type
2.5 IBS-C Drugs Market Competitive Situation and Trends
2.5.1 IBS-C Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest IBS-C Drugs Players Market Share by Revenue
2.5.3 Global IBS-C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 IBS-C Drugs Retrospective Market Scenario by Region
3.1 Global IBS-C Drugs Retrospective Market Scenario in Sales by Region: 2017-2023
3.2 Global IBS-C Drugs Retrospective Market Scenario in Revenue by Region: 2017-2023
3.3 North America IBS-C Drugs Market Facts & Figures by Country
3.3.1 North America IBS-C Drugs Sales by Country
3.3.2 North America IBS-C Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe IBS-C Drugs Market Facts & Figures by Country
3.4.1 Europe IBS-C Drugs Sales by Country
3.4.2 Europe IBS-C Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific IBS-C Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific IBS-C Drugs Sales by Region
3.5.2 Asia Pacific IBS-C Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America IBS-C Drugs Market Facts & Figures by Country
3.6.1 Latin America IBS-C Drugs Sales by Country
3.6.2 Latin America IBS-C Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa IBS-C Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa IBS-C Drugs Sales by Country
3.7.2 Middle East and Africa IBS-C Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global IBS-C Drugs Historic Market Analysis by Type
4.1 Global IBS-C Drugs Sales Market Share by Type (2017-2023)
4.2 Global IBS-C Drugs Revenue Market Share by Type (2017-2023)
4.3 Global IBS-C Drugs Price by Type (2017-2023)
5 Global IBS-C Drugs Historic Market Analysis by Application
5.1 Global IBS-C Drugs Sales Market Share by Application (2017-2023)
5.2 Global IBS-C Drugs Revenue Market Share by Application (2017-2023)
5.3 Global IBS-C Drugs Price by Application (2017-2023)
6 Key Companies Profiled
6.1 Catalent Pharmaceuticals Solutions
6.1.1 Catalent Pharmaceuticals Solutions Corporation Information
6.1.2 Catalent Pharmaceuticals Solutions Description and Business Overview
6.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.1.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio
6.1.5 Catalent Pharmaceuticals Solutions Recent Developments/Updates
6.2 Nestle
6.2.1 Nestle Corporation Information
6.2.2 Nestle Description and Business Overview
6.2.3 Nestle IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.2.4 Nestle IBS-C Drugs Product Portfolio
6.2.5 Nestle Recent Developments/Updates
6.3 Abbott Laboratories
6.3.1 Abbott Laboratories Corporation Information
6.3.2 Abbott Laboratories Description and Business Overview
6.3.3 Abbott Laboratories IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.3.4 Abbott Laboratories IBS-C Drugs Product Portfolio
6.3.5 Abbott Laboratories Recent Developments/Updates
6.4 Synergy Pharmaceuticals
6.4.1 Synergy Pharmaceuticals Corporation Information
6.4.2 Synergy Pharmaceuticals Description and Business Overview
6.4.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Synergy Pharmaceuticals IBS-C Drugs Product Portfolio
6.4.5 Synergy Pharmaceuticals Recent Developments/Updates
6.5 Sucampo Pharmaceuticals
6.5.1 Sucampo Pharmaceuticals Corporation Information
6.5.2 Sucampo Pharmaceuticals Description and Business Overview
6.5.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.5.4 Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio
6.5.5 Sucampo Pharmaceuticals Recent Developments/Updates
6.6 Novartis Pharma Ag
6.6.1 Novartis Pharma Ag Corporation Information
6.6.2 Novartis Pharma Ag Description and Business Overview
6.6.3 Novartis Pharma Ag IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.6.4 Novartis Pharma Ag IBS-C Drugs Product Portfolio
6.6.5 Novartis Pharma Ag Recent Developments/Updates
6.7 Astellas Pharmaceuticals
6.6.1 Astellas Pharmaceuticals Corporation Information
6.6.2 Astellas Pharmaceuticals Description and Business Overview
6.6.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Astellas Pharmaceuticals IBS-C Drugs Product Portfolio
6.7.5 Astellas Pharmaceuticals Recent Developments/Updates
6.8 Ardelyx, Inc
6.8.1 Ardelyx, Inc Corporation Information
6.8.2 Ardelyx, Inc Description and Business Overview
6.8.3 Ardelyx, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.8.4 Ardelyx, Inc IBS-C Drugs Product Portfolio
6.8.5 Ardelyx, Inc Recent Developments/Updates
6.9 Synthetic Biologics, Inc
6.9.1 Synthetic Biologics, Inc Corporation Information
6.9.2 Synthetic Biologics, Inc Description and Business Overview
6.9.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.9.4 Synthetic Biologics, Inc IBS-C Drugs Product Portfolio
6.9.5 Synthetic Biologics, Inc Recent Developments/Updates
6.10 Teva Pharmaceutical Industries
6.10.1 Teva Pharmaceutical Industries Corporation Information
6.10.2 Teva Pharmaceutical Industries Description and Business Overview
6.10.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.10.4 Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio
6.10.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.11 Bama-Geve, SLU
6.11.1 Bama-Geve, SLU Corporation Information
6.11.2 Bama-Geve, SLU IBS-C Drugs Description and Business Overview
6.11.3 Bama-Geve, SLU IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.11.4 Bama-Geve, SLU IBS-C Drugs Product Portfolio
6.11.5 Bama-Geve, SLU Recent Developments/Updates
6.12 Ferring BV
6.12.1 Ferring BV Corporation Information
6.12.2 Ferring BV IBS-C Drugs Description and Business Overview
6.12.3 Ferring BV IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.12.4 Ferring BV IBS-C Drugs Product Portfolio
6.12.5 Ferring BV Recent Developments/Updates
6.13 Ironwood Pharmaceuticals, Inc
6.13.1 Ironwood Pharmaceuticals, Inc Corporation Information
6.13.2 Ironwood Pharmaceuticals, Inc IBS-C Drugs Description and Business Overview
6.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.13.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio
6.13.5 Ironwood Pharmaceuticals, Inc Recent Developments/Updates
6.14 Salix Pharmaceuticals Ltd
6.14.1 Salix Pharmaceuticals Ltd Corporation Information
6.14.2 Salix Pharmaceuticals Ltd IBS-C Drugs Description and Business Overview
6.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio
6.14.5 Salix Pharmaceuticals Ltd Recent Developments/Updates
6.15 Norgine B.V
6.15.1 Norgine B.V Corporation Information
6.15.2 Norgine B.V IBS-C Drugs Description and Business Overview
6.15.3 Norgine B.V IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.15.4 Norgine B.V IBS-C Drugs Product Portfolio
6.15.5 Norgine B.V Recent Developments/Updates
6.16 Prometheus Laboratories Inc
6.16.1 Prometheus Laboratories Inc Corporation Information
6.16.2 Prometheus Laboratories Inc IBS-C Drugs Description and Business Overview
6.16.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.16.4 Prometheus Laboratories Inc IBS-C Drugs Product Portfolio
6.16.5 Prometheus Laboratories Inc Recent Developments/Updates
6.17 Actavis Nordic A/S
6.17.1 Actavis Nordic A/S Corporation Information
6.17.2 Actavis Nordic A/S IBS-C Drugs Description and Business Overview
6.17.3 Actavis Nordic A/S IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.17.4 Actavis Nordic A/S IBS-C Drugs Product Portfolio
6.17.5 Actavis Nordic A/S Recent Developments/Updates
6.18 Albireo Pharma Inc
6.18.1 Albireo Pharma Inc Corporation Information
6.18.2 Albireo Pharma Inc IBS-C Drugs Description and Business Overview
6.18.3 Albireo Pharma Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.18.4 Albireo Pharma Inc IBS-C Drugs Product Portfolio
6.18.5 Albireo Pharma Inc Recent Developments/Updates
6.19 Yuhan Corp
6.19.1 Yuhan Corp Corporation Information
6.19.2 Yuhan Corp IBS-C Drugs Description and Business Overview
6.19.3 Yuhan Corp IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.19.4 Yuhan Corp IBS-C Drugs Product Portfolio
6.19.5 Yuhan Corp Recent Developments/Updates
6.20 Astrazeneca Plc
6.20.1 Astrazeneca Plc Corporation Information
6.20.2 Astrazeneca Plc IBS-C Drugs Description and Business Overview
6.20.3 Astrazeneca Plc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.20.4 Astrazeneca Plc IBS-C Drugs Product Portfolio
6.20.5 Astrazeneca Plc Recent Developments/Updates
6.21 The Menarini Group
6.21.1 The Menarini Group Corporation Information
6.21.2 The Menarini Group IBS-C Drugs Description and Business Overview
6.21.3 The Menarini Group IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.21.4 The Menarini Group IBS-C Drugs Product Portfolio
6.21.5 The Menarini Group Recent Developments/Updates
6.22 Ono Pharmaceutical Co., Ltd
6.22.1 Ono Pharmaceutical Co., Ltd Corporation Information
6.22.2 Ono Pharmaceutical Co., Ltd IBS-C Drugs Description and Business Overview
6.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.22.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio
6.22.5 Ono Pharmaceutical Co., Ltd Recent Developments/Updates
7 IBS-C Drugs Manufacturing Cost Analysis
7.1 IBS-C Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of IBS-C Drugs
7.4 IBS-C Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 IBS-C Drugs Distributors List
8.3 IBS-C Drugs Customers
9 IBS-C Drugs Market Dynamics
9.1 IBS-C Drugs Industry Trends
9.2 IBS-C Drugs Market Drivers
9.3 IBS-C Drugs Market Challenges
9.4 IBS-C Drugs Market Restraints
10 Global Market Forecast
10.1 IBS-C Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of IBS-C Drugs by Type (2023-2030)
10.1.2 Global Forecasted Revenue of IBS-C Drugs by Type (2023-2030)
10.2 IBS-C Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of IBS-C Drugs by Application (2023-2030)
10.2.2 Global Forecasted Revenue of IBS-C Drugs by Application (2023-2030)
10.3 IBS-C Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of IBS-C Drugs by Region (2023-2030)
10.3.2 Global Forecasted Revenue of IBS-C Drugs by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global IBS-C Drugs Sales Growth Rate Comparison by Type (2023-2030) & (K Pcs) & (US$ Million)
Table 2. Global IBS-C Drugs Sales Growth Rate Comparison by Application (2023-2030) & (K Pcs) & (US$ Million)
Table 3. Global IBS-C Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2030)
Table 4. Global IBS-C Drugs Market Competitive Situation by Manufacturers in 2021
Table 5. Global IBS-C Drugs Sales (K Pcs) of Key Manufacturers (2017-2023)
Table 6. Global IBS-C Drugs Sales Market Share by Manufacturers (2017-2023)
Table 7. Global IBS-C Drugs Revenue (US$ Million) by Manufacturers (2017-2023)
Table 8. Global IBS-C Drugs Revenue Share by Manufacturers (2017-2023)
Table 9. Global Market IBS-C Drugs Average Price (USD/Pcs) of Key Manufacturers (2017-2023)
Table 10. Manufacturers IBS-C Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers IBS-C Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global IBS-C Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS-C Drugs as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global IBS-C Drugs Sales by Region (2017-2023) & (K Pcs)
Table 16. Global IBS-C Drugs Sales Market Share by Region (2017-2023)
Table 17. Global IBS-C Drugs Revenue by Region (2017-2023) & (US$ Million)
Table 18. Global IBS-C Drugs Revenue Market Share by Region (2017-2023)
Table 19. North America IBS-C Drugs Sales by Country (2017-2023) & (K Pcs)
Table 20. North America IBS-C Drugs Sales Market Share by Country (2017-2023)
Table 21. North America IBS-C Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 22. North America IBS-C Drugs Revenue Market Share by Country (2017-2023)
Table 23. Europe IBS-C Drugs Sales by Country (2017-2023) & (K Pcs)
Table 24. Europe IBS-C Drugs Sales Market Share by Country (2017-2023)
Table 25. Europe IBS-C Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 26. Europe IBS-C Drugs Revenue Market Share by Country (2017-2023)
Table 27. Asia Pacific IBS-C Drugs Sales by Region (2017-2023) & (K Pcs)
Table 28. Asia Pacific IBS-C Drugs Sales Market Share by Region (2017-2023)
Table 29. Asia Pacific IBS-C Drugs Revenue by Region (2017-2023) & (US$ Million)
Table 30. Asia Pacific IBS-C Drugs Revenue Market Share by Region (2017-2023)
Table 31. Latin America IBS-C Drugs Sales by Country (2017-2023) & (K Pcs)
Table 32. Latin America IBS-C Drugs Sales Market Share by Country (2017-2023)
Table 33. Latin America IBS-C Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 34. Latin America IBS-C Drugs Revenue Market Share by Country (2017-2023)
Table 35. Middle East and Africa IBS-C Drugs Sales by Country (2017-2023) & (K Pcs)
Table 36. Middle East and Africa IBS-C Drugs Sales Market Share by Country (2017-2023)
Table 37. Middle East and Africa IBS-C Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 38. Middle East and Africa IBS-C Drugs Revenue Market Share by Country (2017-2023)
Table 39. Global IBS-C Drugs Sales by Type (2017-2023) & (K Pcs)
Table 40. Global IBS-C Drugs Sales Market Share by Type (2017-2023)
Table 41. Global IBS-C Drugs Revenue by Type (2017-2023) & (US$ Million)
Table 42. Global IBS-C Drugs Revenue Share by Type (2017-2023)
Table 43. Global IBS-C Drugs Price by Type (2017-2023) & (USD/Pcs)
Table 44. Global IBS-C Drugs Sales (K Pcs) by Application (2017-2023)
Table 45. Global IBS-C Drugs Sales Market Share by Application (2017-2023)
Table 46. Global IBS-C Drugs Revenue by Application (2017-2023) & (US$ Million)
Table 47. Global IBS-C Drugs Revenue Share by Application (2017-2023)
Table 48. Global IBS-C Drugs Price by Application (2017-2023) & (USD/Pcs)
Table 49. Catalent Pharmaceuticals Solutions Corporation Information
Table 50. Catalent Pharmaceuticals Solutions Description and Business Overview
Table 51. Catalent Pharmaceuticals Solutions IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 52. Catalent Pharmaceuticals Solutions IBS-C Drugs Product
Table 53. Catalent Pharmaceuticals Solutions Recent Developments/Updates
Table 54. Nestle Corporation Information
Table 55. Nestle Description and Business Overview
Table 56. Nestle IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 57. Nestle IBS-C Drugs Product
Table 58. Nestle Recent Developments/Updates
Table 59. Abbott Laboratories Corporation Information
Table 60. Abbott Laboratories Description and Business Overview
Table 61. Abbott Laboratories IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 62. Abbott Laboratories IBS-C Drugs Product
Table 63. Abbott Laboratories Recent Developments/Updates
Table 64. Synergy Pharmaceuticals Corporation Information
Table 65. Synergy Pharmaceuticals Description and Business Overview
Table 66. Synergy Pharmaceuticals IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 67. Synergy Pharmaceuticals IBS-C Drugs Product
Table 68. Synergy Pharmaceuticals Recent Developments/Updates
Table 69. Sucampo Pharmaceuticals Corporation Information
Table 70. Sucampo Pharmaceuticals Description and Business Overview
Table 71. Sucampo Pharmaceuticals IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 72. Sucampo Pharmaceuticals IBS-C Drugs Product
Table 73. Sucampo Pharmaceuticals Recent Developments/Updates
Table 74. Novartis Pharma Ag Corporation Information
Table 75. Novartis Pharma Ag Description and Business Overview
Table 76. Novartis Pharma Ag IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 77. Novartis Pharma Ag IBS-C Drugs Product
Table 78. Novartis Pharma Ag Recent Developments/Updates
Table 79. Astellas Pharmaceuticals Corporation Information
Table 80. Astellas Pharmaceuticals Description and Business Overview
Table 81. Astellas Pharmaceuticals IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 82. Astellas Pharmaceuticals IBS-C Drugs Product
Table 83. Astellas Pharmaceuticals Recent Developments/Updates
Table 84. Ardelyx, Inc Corporation Information
Table 85. Ardelyx, Inc Description and Business Overview
Table 86. Ardelyx, Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 87. Ardelyx, Inc IBS-C Drugs Product
Table 88. Ardelyx, Inc Recent Developments/Updates
Table 89. Synthetic Biologics, Inc Corporation Information
Table 90. Synthetic Biologics, Inc Description and Business Overview
Table 91. Synthetic Biologics, Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 92. Synthetic Biologics, Inc IBS-C Drugs Product
Table 93. Synthetic Biologics, Inc Recent Developments/Updates
Table 94. Teva Pharmaceutical Industries Corporation Information
Table 95. Teva Pharmaceutical Industries Description and Business Overview
Table 96. Teva Pharmaceutical Industries IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 97. Teva Pharmaceutical Industries IBS-C Drugs Product
Table 98. Teva Pharmaceutical Industries Recent Developments/Updates
Table 99. Bama-Geve, SLU Corporation Information
Table 100. Bama-Geve, SLU Description and Business Overview
Table 101. Bama-Geve, SLU IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 102. Bama-Geve, SLU IBS-C Drugs Product
Table 103. Bama-Geve, SLU Recent Developments/Updates
Table 104. Ferring BV Corporation Information
Table 105. Ferring BV Description and Business Overview
Table 106. Ferring BV IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 107. Ferring BV IBS-C Drugs Product
Table 108. Ferring BV Recent Developments/Updates
Table 109. Ironwood Pharmaceuticals, Inc Corporation Information
Table 110. Ironwood Pharmaceuticals, Inc Description and Business Overview
Table 111. Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 112. Ironwood Pharmaceuticals, Inc IBS-C Drugs Product
Table 113. Ironwood Pharmaceuticals, Inc Recent Developments/Updates
Table 114. Salix Pharmaceuticals Ltd Corporation Information
Table 115. Salix Pharmaceuticals Ltd Description and Business Overview
Table 116. Salix Pharmaceuticals Ltd IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 117. Salix Pharmaceuticals Ltd IBS-C Drugs Product
Table 118. Salix Pharmaceuticals Ltd Recent Developments/Updates
Table 119. Norgine B.V Corporation Information
Table 120. Norgine B.V Description and Business Overview
Table 121. Norgine B.V IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 122. Norgine B.V IBS-C Drugs Product
Table 123. Norgine B.V Recent Developments/Updates
Table 124. Prometheus Laboratories Inc Corporation Information
Table 125. Prometheus Laboratories Inc Description and Business Overview
Table 126. Prometheus Laboratories Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 127. Prometheus Laboratories Inc IBS-C Drugs Product
Table 128. Prometheus Laboratories Inc Recent Developments/Updates
Table 129. Actavis Nordic A/S Corporation Information
Table 130. Actavis Nordic A/S Description and Business Overview
Table 131. Actavis Nordic A/S IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 132. Actavis Nordic A/S IBS-C Drugs Product
Table 133. Actavis Nordic A/S Recent Developments/Updates
Table 134. Albireo Pharma Inc Corporation Information
Table 135. Albireo Pharma Inc Description and Business Overview
Table 136. Albireo Pharma Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 137. Albireo Pharma Inc IBS-C Drugs Product
Table 138. Albireo Pharma Inc Recent Developments/Updates
Table 139. Yuhan Corp Corporation Information
Table 140. Yuhan Corp Description and Business Overview
Table 141. Yuhan Corp IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 142. Yuhan Corp IBS-C Drugs Product
Table 143. Yuhan Corp Recent Developments/Updates
Table 144. Astrazeneca Plc Corporation Information
Table 145. Astrazeneca Plc Description and Business Overview
Table 146. Astrazeneca Plc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 147. Astrazeneca Plc IBS-C Drugs Product
Table 148. Astrazeneca Plc Recent Developments/Updates
Table 149. The Menarini Group Corporation Information
Table 150. The Menarini Group Description and Business Overview
Table 151. The Menarini Group IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 152. The Menarini Group IBS-C Drugs Product
Table 153. The Menarini Group Recent Developments/Updates
Table 154. Ono Pharmaceutical Co., Ltd Corporation Information
Table 155. Ono Pharmaceutical Co., Ltd Description and Business Overview
Table 156. Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 157. Ono Pharmaceutical Co., Ltd IBS-C Drugs Product
Table 158. Ono Pharmaceutical Co., Ltd Recent Developments/Updates
Table 159. Production Base and Market Concentration Rate of Raw Material
Table 160. Key Suppliers of Raw Materials
Table 161. IBS-C Drugs Distributors List
Table 162. IBS-C Drugs Customers List
Table 163. IBS-C Drugs Market Trends
Table 164. IBS-C Drugs Market Drivers
Table 165. IBS-C Drugs Market Challenges
Table 166. IBS-C Drugs Market Restraints
Table 167. Global IBS-C Drugs Sales Forecast by Type (2023-2030) & (K Pcs)
Table 168. Global IBS-C Drugs Sales Market Share Forecast by Type (2023-2030)
Table 169. Global IBS-C Drugs Revenue Forecast by Type (2023-2030) & (US$ Million)
Table 170. Global IBS-C Drugs Revenue Market Share Forecast by Type (2023-2030)
Table 171. Global IBS-C Drugs Sales Forecast by Application (2023-2030) & (K Pcs)
Table 172. Global IBS-C Drugs Sales Market Share Forecast by Application (2023-2030)
Table 173. Global IBS-C Drugs Revenue Forecast by Application (2023-2030) & (US$ Million)
Table 174. Global IBS-C Drugs Revenue Market Share Forecast by Application (2023-2030)
Table 175. Global IBS-C Drugs Sales Forecast by Region (2023-2030) & (K Pcs)
Table 176. Global IBS-C Drugs Sales Market Share Forecast by Region (2023-2030)
Table 177. Global IBS-C Drugs Revenue Forecast by Region (2023-2030) & (US$ Million)
Table 178. Global IBS-C Drugs Revenue Market Share Forecast by Region (2023-2030)
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of IBS-C Drugs
Figure 2. Global IBS-C Drugs Market Share by Type in 2021 & 2030
Figure 3. Linaclotide Product Picture
Figure 4. Lubiprostone Product Picture
Figure 5. Osmotic Laxatives Product Picture
Figure 6. Stimulant Laxatives Product Picture
Figure 7. Others Product Picture
Figure 8. Global IBS-C Drugs Market Share by Application in 2021 & 2030
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. Global IBS-C Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2030
Figure 13. Global IBS-C Drugs Market Size (2017-2030) & (US$ Million)
Figure 14. Global IBS-C Drugs Sales (2017-2030) & (K Pcs)
Figure 15. IBS-C Drugs Sales Share by Manufacturers in 2021
Figure 16. Global IBS-C Drugs Revenue Share by Manufacturers in 2021
Figure 17. The Global 5 and 10 Largest IBS-C Drugs Players: Market Share by Revenue in 2021
Figure 18. IBS-C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 19. Global IBS-C Drugs Sales Market Share by Region (2017-2023)
Figure 20. Global IBS-C Drugs Sales Market Share by Region in 2021
Figure 21. Global IBS-C Drugs Revenue Market Share by Region (2017-2023)
Figure 22. Global IBS-C Drugs Revenue Market Share by Region in 2021
Figure 23. U.S. IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 24. Canada IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 25. Germany IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 26. France IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 27. U.K. IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 28. Italy IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 29. Russia IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 30. China IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 31. Japan IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 32. South Korea IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 33. India IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 34. Australia IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 35. Taiwan IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 36. Indonesia IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 37. Thailand IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 38. Malaysia IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 39. Philippines IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 40. Vietnam IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 41. Mexico IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 42. Brazil IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 43. Argentina IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 44. Turkey IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 45. Saudi Arabia IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 46. U.A.E IBS-C Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 47. Sales Market Share of IBS-C Drugs by Type (2017-2023)
Figure 48. Manufacturing Cost Structure of IBS-C Drugs
Figure 49. Manufacturing Process Analysis of IBS-C Drugs
Figure 50. IBS-C Drugs Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
